Research
Cellular
The use of anti-obesity medications in patients with heart failure may improve functional status, biomarkers of inflammation, and heart failure stability.
Anti-obesity medications may not only aid in weight loss but also enhance overall heart failure management.
StrongSupportsmedium confidence
confirm safety and weight loss efficacy in this patient population as well as improvements in HF functional status, biomarkers of inflammation and HF stability.
Why this rating
The claim is based on clinical trial data.
Source
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Josephine Harrington et al. · Circulation Heart Failure · 2024
DOI 10.1161/circheartfailure.124.011518
reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.Strong
- There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →